diabetesCardio-renal-metabolic syndromeCRMcardiovascular diseaseT2DCKDchronic kidney diseaseDapagliflozinEmpagliflozinGLP-1RA+2 more
…ness-to-pay thresholds. Dapagliflozin was cost saving in type 2 diabetes (T2D) in the United Kingdom (UK) and Spain, reducing HF hospita…